Despite remarkable advances in molecular and cell biology of acute myeloid leukemia(AML),AML patients still frequently relapse and have low 5-year overall survival(OS)rates.1 It is worth noting that a recent study fro...Despite remarkable advances in molecular and cell biology of acute myeloid leukemia(AML),AML patients still frequently relapse and have low 5-year overall survival(OS)rates.1 It is worth noting that a recent study from the registry or clinical trial compilation has reported an improvement in the OS of adult AML patients,especially those under 60 years of age.展开更多
基金supported by the Key Project of the National Natural Science Foundation of China(No.82230088 to R.R.)National Natural Science Foundation of China(No.81870112,82170147 to R.R.,No.81970134,82170111 to P.L.,No.82200200 to Z.X.)+4 种基金Shanghai Science and Technology Development Funds(China)(No.20Z11900200 to R.R.,No.18ZR1423600 to P.L)Shanghai Collaborative Innovation Program on Regenerative Medicine and Stem Cell Research(China)(No.2019CXJQ01 to R.R.)the Samuel Waxman Cancer Research Foundation(to R.R.)the Innovative Research Team of High-level Local Universities in Shanghai,China(to R.R.)the National Key Research and Development Program of China(No.2022YFC2705004 to P.L.).
文摘Despite remarkable advances in molecular and cell biology of acute myeloid leukemia(AML),AML patients still frequently relapse and have low 5-year overall survival(OS)rates.1 It is worth noting that a recent study from the registry or clinical trial compilation has reported an improvement in the OS of adult AML patients,especially those under 60 years of age.
